Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effects of bright light therapy BLT on adolescents aged 13 to 17 with Major Depressive Disorder MDD, a common and disabling condition in this age group. This multicenter, randomized, controlled, double-blind study aims to assess BLTs clinical effectiveness, safety, how quickly it works, and possible brain mechanisms involved in improving mood and cognitive function. The study includes untreated adolescents or those stable on medication and also collects brain imaging data to explore neural changes. Participants are randomly assigned to one of three groups high-intensity bright white light 10,000 lux, medium-intensity bright white light 5,000 lux, or a placebo group receiving dim red light 100 lux. Each group undergoes 40 minutes of light exposure every morning between 630 and 1000 AM, six days a week for four weeks. The therapy is home-based with specific distances from the light source depending on the group. Healthy adolescent controls will also be included for comparison, and brain imaging data will be collected before and after the intervention. During the study, participants will have weekly follow-up assessments during the light therapy period and continue to be monitored for two weeks after treatment ends. Researchers will measure changes in depression severity using the Hamilton Depression Rating Scale-17 and track other outcomes like anxiety, sleep quality, cognitive tests, irritability, suicidal thoughts, self-injury behaviors, and side effects. This trial aims to provide detailed information about BLTs safety and benefits for adolescent depression over approximately six weeks.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the effects of bright light therapy BLT on cognitive impairment in adults with major depressive disorder MDD. This study aims to validate the safety and effectiveness of BLT for improving cognitive function, understand brain circuit changes related to treatment, and explore how these brain changes influence cognitive outcomes. Participants must be adults with MDD, either on stable selective serotonin reuptake inhibitor SSRI monotherapy for at least four weeks or medication-free before joining. Participants will be randomly assigned to one of two groups the experimental group receiving bright light therapy at 10,000 lux, or the control group receiving dim red light at less than 100 lux. Both groups will undergo their respective light interventions for 40 minutes per day, six days a week, between 7 AM and 10 AM, for four weeks. The study includes a follow-up visit four weeks after the intervention ends. During the study, participants will keep a daily record of light exposure and complete a sleep diary. Throughout the study, various assessments will be conducted to evaluate cognitive function, depression, anxiety, sleep quality, quality of life, and side effects. These include standardized cognitive tests, depression and anxiety rating scales, sleep and quality of life questionnaires, and safety evaluations. Functional and structural MRI scans will be performed before and after the intervention to observe brain changes. Evaluations occur at baseline and multiple time points during and after treatment, with ongoing monitoring of symptoms and treatment adherence.
Actively Recruiting
Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.
Actively Recruiting
Researchers are evaluating Shuxuening injection, a multi-target neuroprotective agent, to see its effects when added to intravenous thrombolysis therapy in patients with acute ischemic stroke. This large, multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of Shuxuening injection in improving outcomes after stroke. Intravenous thrombolysis with rt-PA is the current standard treatment, but many patients still experience significant disability, so neuroprotective agents like Shuxuening may help reduce brain cell death. Participants will be randomly assigned to one of two groups one group will receive Shuxuening injection combined with intravenous thrombolysis, and the other will receive a placebo combined with intravenous thrombolysis. Both treatments involve a daily intravenous drip of 20 ml Shuxuening or placebo plus 250 ml of 0.9% sodium chloride for 10 to 14 days. The study plans to enroll 1380 patients within 6 hours of stroke onset from 50 centers across China. During the study, participants will be monitored closely with assessments including the modified Rankin Scale mRS score at 90 days to measure functional recovery, along with safety monitoring for adverse events over 90 days. Other evaluations include neurological function scores, quality of life surveys, and various safety outcomes. The trial will last for at least 90 days after treatment, with data collected on disability, recovery, and any side effects experienced.
Actively Recruiting
Researchers are studying the prevalence of chronic obstructive pulmonary disease COPD among participants aged 40 years or older who have one of three types of cardiovascular diseases coronary heart disease, atrial fibrillation, or chronic heart failure. This multi-center, prospective, interventional study aims to understand how cardiopulmonary co-management affects the short-term health outcomes of participants with both cardiovascular disease and COPD. Approximately 3,000 participants will be enrolled, with about 1,000 in each disease cohort. The study intervention includes guideline education and implementation at both the investigator and patient levels. Investigators receive education on COPD and cardiovascular disease about four weeks before enrolling participants. After enrollment, cardiologists and pulmonologists provide disease education every four weeks, along with collaborative treatment management for participants with both conditions. Participants are followed up every four weeks throughout the study. During the study, participants will undergo spirometry testing, complete questionnaires, and have various health measures recorded, including hospitalization rates and scores related to heart and lung function. Researchers will also monitor lung function tests, blood markers, and medication use at baseline and at weeks 4, 8, and 12. The primary outcome is the number and percentage of participants with COPD across the cardiovascular disease cohorts. The study includes short-term follow-up over 12 weeks to observe treatment and health changes.
Actively Recruiting
Researchers are evaluating the preliminary effectiveness and safety of Tislelizumab combined with thoracic radiotherapy and chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer. This is a phase II, single-arm, open, multicenter study aiming to explore this combination therapy in people newly diagnosed with this condition. Participants will receive Tislelizumab infusions 200 mg every 3 weeks for up to 2 years. They will also receive chemotherapy with Etoposide plus either Carboplatin or Cisplatin for 4 cycles every 3 weeks. Concurrent thoracic radiotherapy will be given using intensity-modulated radiation therapy IMRT with doses between 30 to 45 Gy over 10 to 15 fractions. Throughout the study, participants will be closely monitored with imaging to assess tumor response and disease progression for up to 2 years. Researchers will track progression-free survival as the main outcome, along with response rates, overall survival, and any side effects. Participants will have regular visits for assessments and follow-ups to monitor treatment effects and safety during and after therapy.